Research Analysts Set Expectations for WVE Q1 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Wave Life Sciences in a research note issued to investors on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz expects that the company will earn ($0.28) per share for the quarter. The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share. Leerink Partnrs also issued estimates for Wave Life Sciences' Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.13) EPS and FY2026 earnings at ($1.12) EPS.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.34. The company had revenue of $83.75 million for the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.

A number of other brokerages also recently commented on WVE. StockNews.com raised shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. HC Wainwright reissued a "buy" rating and set a $22.00 target price on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Finally, Jefferies Financial Group began coverage on shares of Wave Life Sciences in a report on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price target on the stock. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.60.

Remove Ads

Wave Life Sciences Stock Down 7.0 %

NASDAQ:WVE traded down $0.53 during midday trading on Monday, hitting $7.04. The stock had a trading volume of 366,975 shares, compared to its average volume of 1,058,849. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -6.34 and a beta of -0.93. Wave Life Sciences has a one year low of $4.25 and a one year high of $16.74. The stock has a 50-day moving average of $10.53 and a 200 day moving average of $11.72.

Institutional Trading of Wave Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new position in Wave Life Sciences in the 4th quarter valued at approximately $40,000. Quarry LP purchased a new position in Wave Life Sciences in the fourth quarter valued at $62,000. KBC Group NV purchased a new position in Wave Life Sciences in the fourth quarter valued at $67,000. Point72 DIFC Ltd purchased a new stake in Wave Life Sciences during the 3rd quarter worth about $98,000. Finally, Summit Investment Advisors Inc. increased its stake in shares of Wave Life Sciences by 31.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock worth $119,000 after buying an additional 2,308 shares during the period. Hedge funds and other institutional investors own 89.73% of the company's stock.

Insider Buying and Selling at Wave Life Sciences

In related news, CEO Paul Bolno sold 169,025 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares in the company, valued at approximately $3,238,019.07. This represents a 33.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christian O. Henry sold 10,500 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the transaction, the director now owns 16,115 shares of the company's stock, valued at approximately $157,443.55. This represents a 39.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is owned by corporate insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.